ALKS
Price
$29.95
Change
+$1.03 (+3.56%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
4.94B
46 days until earnings call
AMRX
Price
$9.62
Change
+$0.06 (+0.63%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
3.02B
62 days until earnings call
Interact to see
Advertisement

ALKS vs AMRX

Header iconALKS vs AMRX Comparison
Open Charts ALKS vs AMRXBanner chart's image
Alkermes
Price$29.95
Change+$1.03 (+3.56%)
Volume$40.13K
Capitalization4.94B
Amneal Pharmaceuticals
Price$9.62
Change+$0.06 (+0.63%)
Volume$12.68K
Capitalization3.02B
ALKS vs AMRX Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. AMRX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a StrongBuy and AMRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ALKS: $28.92 vs. AMRX: $9.55)
Brand notoriety: ALKS and AMRX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 112% vs. AMRX: 109%
Market capitalization -- ALKS: $4.94B vs. AMRX: $3.02B
ALKS [@Pharmaceuticals: Generic] is valued at $4.94B. AMRX’s [@Pharmaceuticals: Generic] market capitalization is $3.02B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whileAMRX’s FA Score has 1 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • AMRX’s FA Score: 1 green, 4 red.
According to our system of comparison, ALKS is a better buy in the long-term than AMRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while AMRX’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 4 bearish.
  • AMRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ALKS and AMRX are a good buy in the short-term.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а -0.03% price change this week, while AMRX (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.80%. For the same industry, the average monthly price growth was +10.12%, and the average quarterly price growth was +85.54%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

AMRX is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.80% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.94B) has a higher market cap than AMRX($3.02B). AMRX has higher P/E ratio than ALKS: AMRX (962.00) vs ALKS (14.46). AMRX YTD gains are higher at: 20.581 vs. ALKS (0.556). AMRX has higher annual earnings (EBITDA): 584M vs. ALKS (450M). ALKS has more cash in the bank: 1.02B vs. AMRX (71.5M). ALKS has less debt than AMRX: ALKS (72.7M) vs AMRX (2.58B). AMRX has higher revenues than ALKS: AMRX (2.85B) vs ALKS (1.51B).
ALKSAMRXALKS / AMRX
Capitalization4.94B3.02B164%
EBITDA450M584M77%
Gain YTD0.55620.5813%
P/E Ratio14.46962.002%
Revenue1.51B2.85B53%
Total Cash1.02B71.5M1,421%
Total Debt72.7M2.58B3%
FUNDAMENTALS RATINGS
ALKS vs AMRX: Fundamental Ratings
ALKS
AMRX
OUTLOOK RATING
1..100
1726
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
3952
SMR RATING
1..100
4099
PRICE GROWTH RATING
1..100
5442
P/E GROWTH RATING
1..100
3132
SEASONALITY SCORE
1..100
n/a32

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALKS's Valuation (97) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to AMRX’s over the last 12 months.

ALKS's Profit vs Risk Rating (39) in the Biotechnology industry is in the same range as AMRX (52) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to AMRX’s over the last 12 months.

ALKS's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as ALKS (54) in the Biotechnology industry. This means that AMRX’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's P/E Growth Rating (31) in the Biotechnology industry is in the same range as AMRX (32) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSAMRX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 11 days ago
62%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCEGX15.030.18
+1.21%
BlackRock Unconstrained Equity Inv C
PSCCX28.520.26
+0.92%
PGIM Jennison Small Company C
APSGX17.560.16
+0.92%
NYLI Fiera SMID Growth Class I
HUSIX28.540.23
+0.81%
Huber Small Cap Value Inv
FZAHX232.08N/A
N/A
Fidelity Advisor Growth Opps Z

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
-3.60%
AMRX - ALKS
39%
Loosely correlated
+0.10%
COLL - ALKS
36%
Loosely correlated
-0.91%
PCRX - ALKS
33%
Loosely correlated
-1.66%
PRGO - ALKS
33%
Poorly correlated
-0.17%
DVAX - ALKS
32%
Poorly correlated
-1.48%
More

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+0.10%
PAHC - AMRX
46%
Loosely correlated
+2.29%
VTRS - AMRX
43%
Loosely correlated
-2.09%
TEVA - AMRX
40%
Loosely correlated
-1.49%
COLL - AMRX
39%
Loosely correlated
-0.91%
ALKS - AMRX
38%
Loosely correlated
-3.60%
More